/PRNewswire/ – The board of directors of Eli Lilly and Company has elected Juan R. Luciano as a new member, effective February 1, 2016.
Luciano is chief executive officer and president of Archer Daniels Midland Company (ADM), and a member of the ADM board of directors.
“I am pleased to welcome Juan to the Lilly board,” said John C. Lechleiter, Ph.D., chairman, president and chief executive officer. “Juan brings to the Lilly board a global perspective and a proven track record of leading high-performance, results-focused organizations. We will benefit from Juan’s broad business experience, including his knowledge of the food and agriculture sectors.”
Luciano joined ADM in 2011 as executive vice president and chief operating officer. He was named president in February 2014, and in January 2015 became the ninth chief executive in ADM’s 112-year history.
Since joining ADM, Luciano has overseen the commercial and production activities of ADM’s Corn, Oilseeds and Agricultural Services businesses, as well as its research, project management, procurement and risk management functions. He led the company’s operational excellence initiatives, which seek to improve productivity and efficiency companywide, as well as the company’s efforts to improve its capital, cost and cash positions. Luciano also led the company’s move into ingredients.
Before joining ADM, Luciano had a successful 25-year tenure at The Dow Chemical Company, where he last served as executive vice president and president of the performance division.
Luciano is a governor of the Boys and Girls Clubs of America, and Midwest chair of the organization’s National Trustees Board. He holds an industrial engineering degree from the Buenos Aires Institute of Technology.
Source: Eli Lilly and Company
Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.
Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.
On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.